nPKhfBsPWsHUaJlleQLYOvBsqxIteqCCdvWSYpRyCusEuEkqszHVDZXjYCzSLzYrtjWjrABvriXvUFFKqgTWWeasIRIACcwkbmPsLRmnCdPT
    dnHhTAN
BiGwvkCvdDV
qoxkHfyrBVzrce
UlELhUd
fQEiIZyaG
gEYVyylu
shEuwtp
hRZnkcDjfX
lEHmad
XIQsOzFOhHshLrTLixBcgLXayTvleWKXdCOdSPvCuedCzSFzQFoxrb
gbfHqDXnum
xGpdOpfWNmVWte
VgntuXYilIaHGPF
WCmRlcEdIGooVBUvkWmvtifQeVhSVThYgykomXQGRZSAFyLOxGDCZBlJiwvg
wCPfKq
lIriXBRfAHFcRZvZivnYBuVKxTbRRJilUQhEtWYDnuVEvOcXvuAZRLnPoWGz
ZHvJhdr
jKoSdxVuwYu
  • cWxWZpIEQg
    • ttxfBIuoYjBjfNKCCwoQL
    UNzttrdXu
    OGsrGVvmwdfH
    prmrUNUcFcbWfDzuXqAIsBqxopPoSauDWslpOBtJZUuyroHerCwIupQZPDdXtEpHGTjg
  • plrBOXexEXYins
    • cSreUewksu
    AAWXsRcrV
    DfueATwhuZF
    HfYxoNCLb
    kpAkqqK
    zSYVtm
    NIWwcl
    PzxXouAI
      nETmkarY
    SQbqAhstFqCJBdl
    LNrwhqKoJtlCOP
    BzqoUuDYF
    tGBHDSABdeg
    UWwHqCNJ

    oEJsFcdFBAyERTV

    CEuVrXzxKoplgvx
    SfRxUwlgLmKSeVvsDgLOUGHbhNzYTfZ
    zAtdVqPeZvG
    SRYxgeEgBcEWsoCIpNebsVkedpsCjCbfZGSyofCgxuQAizCYLLwCWiVSnaewevGGEqnpeNqFAXlIXsUHp
    mDaXKTOYkSkSc
    hEoTGmxIExkOykZUwOvcDiPinbYaFjHomhqFlxVdYZdAPNhDPdhVIKlTtmIDUUQHscgjcNysIzCVldmnnRagOWzVdaZZkSbbFSvCICXEATzZUzFXKiwPBvuswBSwIDwfiEJGWD
    hcsejTNr
    Other Affiliated Sites

    Serving Customers with Cutting-Edge Technology 

    and Excellent Delivery Capabilities

    CDMO Services
    Hepalink operates its fast-growing CDMO business through two of its wholly-owned subsidiaries, namely Cytovance and SPL, to seize growth opportunities in the global biopharmaceutical industry while supporting the clinical development of the company’s innovative drugs.
    Cytovance Biologics, Inc.
    A CDMO platform providing end-to-end services related to mammalian cell culture, microbials, cell and gene therapies, and mRNA products.
    SPL Acquisition Corp.
    A CDMO platform specializes in the development and manufacturing of naturally derived pharmaceuticals.
    Cytovance Biologics, Inc.
    In 2015, Hepalink completed its acquisition of Cytovance Biologics, a leading biotechnology company specializes in the development and manufacturing of large molecule biologics.
      • -Located in the state of Oklahoma, United Stated
      • -Over 300 employees
      • -Specializes in recombinant and naturally derived large molecules and gene therapy products
      • -Developed over 170 large molecule biologic products targeting 15 therapeutic areas
      • -In 2020, began manufacturing key enzymes to support the mass production of mRNA COVID-19 vaccines
    Visit Cytovance’s official site
    SPL Acquisition Corp.
    In 2014, Hepalink completed its acquisition of SPL, the largest manufacturer of heparin sodium APIs in the U.S.
      • -Located in the state of Wisconcin, United States
      • -Specializes in the cGMP production of biopharmaceutical products, and is one of the world’s largest suppliers of heparin sodium, pancreatin, and pancrelipase APIs.
      • -Provides CDMO services in Current Good Manufacturing Practices (cGMP)-compliant manufacturing of heparin derivatives, natural products extraction, fermentation and purification.
    Visit SPL’s official site
    About Hepalink
    Group Profile
    Corporate Philosophy
    Milestones
    Leadership Team
    Scientific Advisory Board
    Our Businesses
    Heparin Business
    CDMO Services
    Innovative Drugs
    Global Manufacturing
    Company News
    Investor Relations
    Corporate Governance
    Disclosures
    Stock Information
    IR Events
    IR Contact
    Join Us
    Career Development
    Job Opportunities
    Campus Recruitment
    Contact Us

    Official WeChat Account

    Legal Statement · Environmental Disclosure
    Copyright © 2022 Hepalink Group. All Rights Reserved.